Skip to content
OpenCapital
Get started

Bioventus BVS Pain Treatments — Total Net Sales

Other product segments

Surgical Solutions
$48.03M+6.2%
Restorative Therapies
$20.64M+4.6%

Similar metrics at other companies

Avanos Medical logo
AVNSTotal Pain Management and Recovery — Net Sales
$56.3M+0.2%
Avanos Medical logo
AVNSSurgical pain and recovery — Net Sales
$21.8M-11.0%
Perrigo Company logo
PRGOPain & Sleep — Net Sales
$106.6M-17.8%
AtriCure logo
ATRCPain management — Revenue from Contract with Customer, Excluding Assessed Tax
$24.35M+27.8%
PBH
PBHAnalgesics — Total revenues
$28.24M-6.5%
Baxter International logo
BAXMedical Products & Therapies — Net Sales
$1.29B+1.8%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×—
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's pain treatments — total net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's pain treatments — total net sales?
Bioventus (BVS) reported pain treatments — total net sales of $63.43M in Q1 2026.
How has Bioventus's pain treatments — total net sales changed year-over-year?
Bioventus's pain treatments — total net sales increased by 7.7% year-over-year, from $58.92M to $63.43M.
What is the long-term trend for Bioventus's pain treatments — total net sales?
Over 4 years (2021 to 2025), Bioventus's pain treatments — total net sales has grown at a 5.9% compound annual growth rate (CAGR), from $221.61M to $279.06M.
What does pain treatments — total net sales mean?
This metric represents the total revenue generated from the sale of medical products and therapeutic solutions specifically designed for pain management and orthopedic recovery. It reflects the commercial performance and market adoption of the company's specialized portfolio within the pain treatment segment. Tracking this figure helps investors assess the growth trajectory and demand for the company's core therapeutic offerings.